News and Events

News

All categories

Earnings

Press Release

All years

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

May 29, 2020

Affimed to Present at the Jefferies Virtual Healthcare Conference

May 28, 2020

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK^® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

May 15, 2020

Affimed Reports 2019 Financial Results and Recent Operational Progress

April 28, 2020

Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

April 16, 2020

Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020

April 2, 2020

Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma

April 2, 2020

Affimed Announces Participation at Upcoming Virtual Investor Conferences

March 26, 2020

Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer

March 17, 2020

Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference

February 19, 2020

Events

All

Scientific

Investors

03Jun

ASCO Annual Meeting

June 3 - 7, 2022 (Chicago, US)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

Affimed to Present at the Jefferies Virtual Healthcare Conference

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK^® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

Affimed Reports 2019 Financial Results and Recent Operational Progress

Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020

Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma

Affimed Announces Participation at Upcoming Virtual Investor Conferences

Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer

Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Events

ASCO Annual Meeting